



The next level of profitable growth

Transforming to new levels of profitable growth

Segment Advanced Therapies

Meet the Management,
December 10, 2019



This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This presentation has been prepared for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG. It does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any existing or future member of the Siemens Healthineers Group (the "Group") or Siemens AG, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers AG, any member of the Group or Siemens AG or with any other contract or commitment whatsoever. This presentation does not constitute a prospectus in whole or in part, and any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice. All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto.

The information contained in this presentation has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Siemens Healthineers AG or any of its affiliates, advisers, affiliated persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as "expect", "forecast", "anticipate", "intend", "plan", "believe", "seek", "estimate", "will", "target" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers' management, of which many are beyond Siemens Healthineers' control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. All forward-looking statements refer to the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures (financial key performance indicators) that are or may be alternative performance measures (non-GAAP measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers' net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable. Please find further explanations regarding our financial key performance indicators in the respective Annual Reports of Siemens Healthineers under the following internet link <https://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications>.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.


The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.



**Advanced
imaging**
to enhance minimally
invasive procedures

Addressing core with next generation image guidance and unprecedented image quality

Cristal clear
device visibility



Anatomy not seen
on Angiography before



How did you find UBS, 5 Broadgate?



How did you find UBS, 5 Broadgate?





Image quality and navigation guidance help you to get where you want

Example: Minimally invasive cancer treatment with “Embolization Guidance”



Traditional imaging, liver tumor hardly visible



Imaging with Tumor-Enhancement

Courtesy: Prof. Thomas Vogl, JWG University of Frankfurt, Germany

Embolization guidance with 3D tumor margin and feeding vessels roadmap





Image quality and navigation guidance help you to get where you want

Example Minimally invasive cancer treatment with “Embolization Guidance”



Traditional imaging, liver tumor hardly visible




Imaging with Tumor-Enhancement

Courtesy: Prof. Thomas Vogl, JWG University of Frankfurt, Germany

Embolization guidance with 3D tumor margin and feeding vessels roadmap



Addressing core with next generation image guidance



Key value propositions of ARTIS icono

- **Connected and digital** interventional suite
- Unprecedented image quality **making the unseen visible**
- Improved **patient outcomes** with **one stop stroke assessment and therapy**
- **Personalized case workflows** for higher patient throughput
- **Increased utilization** through enabled multi-disciplinary usage – 3-in-1 system

Advanced Therapies – Transforming to new levels of profitable growth

Addressing core with image guidance and navigation

- **Enhancing** minimally invasive **procedures** with ARTIS icono
- **Reinforcing portfolio** and **coverage** in fast growing geographies
- **Leveraging** the entire Siemens Healthineers **portfolio** for next-gen therapy guidance
- Capitalizing on **service revenue**

Improving precision and transforming care delivery

- **One stop angio based stroke** assessment and therapy with ARTIS icono
- Enhancing physicians eyes and hands with **Corindus**
- Improving **patient access** with **remote** treatment

Expanding in highly growing **procedures**

- Expanding **addressable market**
- Adding **per procedure revenue** by focusing on cardio- and neurovascular procedures where advanced imaging drives better outcomes
- **Broadening scope in cancer therapy** by providing integrated navigation solutions for ablation and embolization

Combining eyes and hands enhancement in a unique integrated system with Corindus

Next generation

Image Guidance

- Imaging that **makes the unseen visible**
- **Connected and digital** interventional suite
- Disruptive potential in angio only **one stop stroke**






Next generation

Treatment Delivery

- **Robotic precision** and procedure transformation
- Potential to enable **remote treatment**



Manual workflow

Manual catheter navigation requires the skills of an experienced physician





Robotic workflow

AI and semi-automated navigation for faster and highly precise treatment guidance





Remote workflow

AI and semi-automated navigation for faster and highly precise treatment guidance



The future starts now

December 4 – 5, 2018




THE
LANCET

**First in-human telerobotic PCI procedure
from 20 miles away**

Dr. Tejas Patel, from Ahmedabad, India

November 1, 2019




First in-human neuro vascular aneurysm coiling

Dr. Vitor Mendes Pereira, The Toronto Western Hospital, Canada


Creating value by complementing imaging system and robotic assistance

Today

High Radiation Exposure


 Shielded operation

High variability in physicians' experience


 Reproducible results

Tomorrow

Complex, long lasting procedures

 Automated procedures

Availability of experienced physicians

 Remote treatment

Protection



Improved ergonomics

Precision




Millimetric robotic drive

Efficiency



Unique integrated system

Access



Expert availability

Robotic assistance and new business models will allow expansion in fast growing procedures



1 CAGR 2013-2024: DRG Medtech 360 report 2018, Canaccord Genuity Analyst Report (May 2019)

2 3' in thrombectomy-capable countries | 3 Global Data 2018, own extrapolation

Advanced Therapies will stepping up by capturing highly growing procedures

Transforming to new levels of growth



Comparable revenue growth¹⁾

>5% towards high-single digit



Gain market share




Grow service steadily



Expand in highly growing procedures

¹ Y-o-y on a comparable basis, excluding translation and portfolio effects



.....

Siemens Healthineers Headquarters

Siemens Healthcare GmbH

Henkestr. 127

91052 Erlangen

Germany

Phone: +49 9131 84-0

[siemens-healthineers.com](https://www.siemens-healthineers.com)

.....

Some solutions described are under development and not available for sale.

There future availability cannot be guaranteed

On account of certain regional limitations of sales rights and service availability, we cannot guarantee that all products included in this presentation are available through the Siemens sales organization worldwide. Availability and packaging may vary by country and are subject to change without prior notice.

The customers cited are employed by an institution that might provide Siemens product reference services, R&D collaboration or other relationship for compensation pursuant to a written agreement.